Melatonin modulation of intracellular signaling pathways in hepatocarcinoma HepG2 cell line: role of the MT1 receptor

Abstract:  Melatonin reduces proliferation in many different cancer cell lines. However, studies on the oncostatic effects of melatonin in hepatocarcinoma are limited. We have previously demonstrated that melatonin administration induces cycle arrest, apoptosis, and changes in the expression of its specific receptors in HepG2 human hepatocarcinoma cells. In this study, we used the receptor antagonist luzindole to assess the contribution of MT1 melatonin membrane receptor to melatonin effects on cell viability, mitogen‐activated protein kinase (MAPKs) activation, and cAMP levels. Additionally, effects of MT1 inhibition on mRNA levels of cytosolic quinone reductase type‐2 (NQO2) receptor and nuclear retinoic acid‐related orphan receptor alpha (RORα) were tested. Melatonin, at 1000 and 2500 μm, significantly reduced cell viability. Pre‐incubation with luzindole partially inhibited the effects of melatonin on cell viability. Melatonin at 2500 μm significantly reduced cAMP levels, and this effect was partially blocked by luzindole. Both melatonin concentrations increased the expression of phosphorylated p38, ERK, and JNK. ERK activation was completely abolished in the presence of luzindole. NQO2 but not RORα mRNA level significantly increased in luzindole‐treated cells. Results obtained provide evidence that the melatonin effects on cell viability and proliferation in HepG2 cells are partially mediated through the MT1 membrane receptor, which seems to be related also with melatonin modulation of cAMP and ERK activation. This study also highlights a possible interplay between MT1 and NQO2 melatonin receptors in liver cancer cells.

[1]  L. Hui,et al.  Mitogen-activated protein kinases in hepatocellular carcinoma development. , 2011, Seminars in cancer biology.

[2]  S. Hill,et al.  Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway , 2010, Breast Cancer Research.

[3]  F. Zamponi,et al.  Molecular organization and dynamics of the melatonin MT1 receptor/RGS20/Gi protein complex reveal asymmetry of receptor dimers for RGS and Gi coupling , 2010, The EMBO journal.

[4]  H. Mukhtar,et al.  Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model , 2010, Journal of pineal research.

[5]  R. Reiter,et al.  Melatonin induces pro‐apoptotic signaling pathway in human pancreatic carcinoma cells (PANC‐1) , 2010, Journal of pineal research.

[6]  S. Hill,et al.  In vitro and in vivo antitumor activity of melatonin receptor agonists , 2010, Journal of pineal research.

[7]  Luigi Frati,et al.  Current approach in the treatment of hepatocellular carcinoma. , 2010, World journal of gastrointestinal oncology.

[8]  C. Liu,et al.  Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway. , 2010, Cellular and molecular biology.

[9]  R. Reiter,et al.  Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK‐MEL‐1 cells , 2010, Journal of pineal research.

[10]  Jiahuai Han,et al.  MAPK signaling in inflammation-associated cancer development , 2010, Protein & Cell.

[11]  Nihal Ahmad,et al.  Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer , 2010, Journal of pineal research.

[12]  Tripp Frasch,et al.  Molecular Mechanisms of Melatonin Anticancer Effects , 2009, Integrative cancer therapies.

[13]  J. González‐Gallego,et al.  Changes in the expression of melatonin receptors induced by melatonin treatment in hepatocarcinoma HepG2 cells , 2009, Journal of pineal research.

[14]  H. Baik,et al.  Melatonin inhibits human fibroblast‐like synoviocyte proliferation via extracellular signal‐regulated protein kinase/P21CIP1/P27KIP1 pathways , 2009, Journal of pineal research.

[15]  S. Joo,et al.  Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer , 2009, Journal of pineal research.

[16]  I. Bazwinsky,et al.  Modulation of the cGMP signaling pathway by melatonin in pancreatic β‐cells , 2009, Journal of pineal research.

[17]  M. Melan,et al.  Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives , 2009, Expert Reviews in Molecular Medicine.

[18]  Josep M. Guerrero,et al.  A novel interplay between membrane and nuclear melatonin receptors in human lymphocytes: significance in IL-2 production , 2009, Cellular and Molecular Life Sciences.

[19]  S. Cuzzocrea,et al.  Melatonin reduces stress‐activated/mitogen‐activated protein kinases in spinal cord injury , 2009, Journal of pineal research.

[20]  J. González‐Gallego,et al.  Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line , 2008, Journal of pineal research.

[21]  H. Manev,et al.  Melatonin signaling in mouse cerebellar granule cells with variable native MT1 and MT2 melatonin receptors , 2008, Brain Research.

[22]  J. González‐Gallego,et al.  Differential effects of dietary flavonoids on reactive oxygen and nitrogen species generation and changes in antioxidant enzyme expression induced by proinflammatory cytokines in Chang Liver cells. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[23]  M. A. Rol,et al.  Effects of exogenous melatonin and circadian synchronization on tumor progression in melanoma‐bearing C57BL6 mice , 2008, Journal of pineal research.

[24]  R. Jockers,et al.  MT1 melatonin receptor internalization underlies melatonin‐induced morphologic changes in Chinese hamster ovary cells and these processes are dependent on Gi proteins, MEK 1/2 and microtubule modulation , 2008, Journal of pineal research.

[25]  D. Acuña-Castroviejo,et al.  Cellular mechanisms involved in the melatonin inhibition of HT‐29 human colon cancer cell proliferation in culture , 2007, Journal of pineal research.

[26]  M. Svoboda,et al.  Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors , 2007, Journal of pineal research.

[27]  J. González‐Gallego,et al.  Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. , 2007, Toxicology.

[28]  Wei Chen,et al.  Differential regulation and properties of MAPKs , 2007, Oncogene.

[29]  A. Slominski,et al.  Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines. , 2006, International journal of oncology.

[30]  Zhirong Wang,et al.  Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. , 2005, Biochemical and biophysical research communications.

[31]  M. Dubocovich,et al.  Functional MT1 and MT2 melatonin receptors in mammals , 2005, Endocrine.

[32]  M. Paquet,et al.  Deficiency of NRH:Quinone Oxidoreductase 2 Increases Susceptibility to 7,12-Dimethylbenz(a)anthracene and Benzo(a)pyrene-Induced Skin Carcinogenesis , 2004, Cancer Research.

[33]  Josep M. Guerrero,et al.  mRNA expression of nuclear receptor RZR/RORα, melatonin membrane receptor MT1, and hydroxindole‐O‐methyltransferase in different populations of human immune cells , 2004, Journal of pineal research.

[34]  A. Carrillo-Vico,et al.  Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. , 2004, Life sciences.

[35]  S. Shiu,et al.  Melatonin slowed the early biochemical progression of hormone‐refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype , 2003, Journal of pineal research.

[36]  M. Itoh,et al.  Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer. , 2003, Journal of pineal research.

[37]  M. Dubocovich,et al.  MT1 melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells , 2002, Molecular and Cellular Endocrinology.

[38]  T. Voyno-Yasenetskaya,et al.  Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins. , 2002, Cellular signalling.

[39]  Y. Yarden,et al.  Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53 , 2001, Oncogene.

[40]  O. Nosjean,et al.  Identification of the Melatonin-binding SiteMT 3 as the Quinone Reductase 2* , 2000, The Journal of Biological Chemistry.

[41]  Christopher Browning,et al.  Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptors , 2000, British journal of pharmacology.

[42]  J. Wong,et al.  Melatonin‐induced inhibition of proliferation and G1/S cell cycle transition delay of human choriocarcinoma JAr cells: Possible involvement of MT2 (MEL1B) receptor , 1999, Journal of pineal research.

[43]  J. Barrett,et al.  The oncostatic action of melatonin in an ovarian carcinoma cell line , 1999, Journal of pineal research.

[44]  D. Kouretas,et al.  Effects of melatonin on proliferation of cancer cell lines , 1998, Journal of pineal research.

[45]  J. Vanecek.  Cellular mechanisms of melatonin action. , 1998, Physiological reviews.

[46]  L. Niles,et al.  Picomolar-affinity binding and inhibition of adenylate cyclase activity by melatonin in syrian hamster hypothalamus , 1990, Cellular and Molecular Neurobiology.

[47]  S. Hill,et al.  Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. , 1988, Cancer research.

[48]  F. Denizot,et al.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. , 1986, Journal of immunological methods.

[49]  R. Alves,et al.  Advanced hepatocellular carcinoma. Review of targeted molecular drugs. , 2011, Annals of hepatology.

[50]  R. Alves,et al.  Advanced hepatocellular carcinoma . Review of targeted molecular drugs , 2011 .

[51]  M. Pawlikowski,et al.  Luzindole but not 4-phenyl-2- propionamidotetralin (4P-PDOT) diminishes the inhibitory effect of melatonin on murine Colon 38 cancer growth in vitro. , 2009, Neuro endocrinology letters.

[52]  Y. Sakuma,et al.  Gene structures, biochemical characterization and distribution of rat melatonin receptors , 2008, The Journal of Physiological Sciences.

[53]  C. Schuster.  [Sites and mechanisms of action of melatonin in mammals: the MT1 and MT2 receptors]. , 2007, Journal de la Societe de biologie.

[54]  Carole Schuster.  Sites et mécanismes d'action de la mélatonine chez les Mammifères: les récepteurs MT1 et MT2. , 2007 .

[55]  M. Dubocovich,et al.  MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. , 2002, Molecular and cellular endocrinology.

[56]  M. Farriol,et al.  In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line , 2000, Journal of applied toxicology : JAT.

[57]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.